Quarterly report · Q2
4583.TEDINET S100S9VE
Period2023-01-01 → 2023-06-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Amends S100RN56.
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥359m | 2023-01-01 → 2023-06-30 | Standalone | Net sales |
| Revenue | ¥631m | 2022-01-01 → 2022-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥278m | 2022-01-01 → 2022-06-30 | Standalone | Net sales |
| Operating income | −¥659m | 2023-01-01 → 2023-06-30 | Standalone | Operating income |
| Operating income | −¥779m | 2022-01-01 → 2022-06-30 | Standalone | Operating income |
| Ordinary income | −¥662m | 2023-01-01 → 2023-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥769m | 2022-01-01 → 2022-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥661m | 2023-01-01 → 2023-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥769m | 2022-01-01 → 2022-06-30 | Standalone | Income before income taxes |
| Net income | −¥664m | 2023-01-01 → 2023-06-30 | Standalone | Profit loss |
| Net income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥771m | 2022-01-01 → 2022-06-30 | Standalone | Profit loss |
| Total assets | ¥1.7bn | at 2023-06-30 | Standalone | Assets |
| Total assets | ¥2.2bn | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥1.9bn | at 2022-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥541m | at 2023-06-30 | Standalone | Liabilities |
| Total liabilities | ¥425m | at 2022-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.1bn | at 2023-06-30 | Standalone | Net assets |
| Net assets / equity | ¥1.8bn | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.5bn | at 2022-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2023-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.7bn | at 2022-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.2bn | at 2023-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2022-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2022-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2021-12-31d | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥595m | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥660m | 2022-01-01 → 2022-06-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | ¥82,000 | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | ¥113m | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥341m | 2022-01-01 → 2022-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-13.7 | 2023-01-01 → 2023-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-9 | 2023-04-01 → 2023-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-28.26 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-18.17 | 2022-01-01 → 2022-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.53 | 2022-04-01 → 2022-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 67.2% | at 2023-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.2% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.3% | at 2022-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 48,503,800 | at 2023-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,423,500 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 43,057,600 | at 2022-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-06-30 | −¥266m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥602m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥359m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥359m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥209m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-06-30 | ¥359m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-06-30 | ¥359m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-06-30 | −¥393m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-06-30 | −¥239m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥691m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥278m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥278m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥151m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-06-30 | ¥278m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-06-30 | ¥278m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-06-30 | −¥540m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 444
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant_NonConsolidatedMember | 1471935000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant_NonConsolidatedMember | 1245431000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 1727270000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration_NonConsolidatedMember | -6.53 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration_NonConsolidatedMember | -9.00 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 48503800 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 49323800 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 48503800 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 49323800 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 2071210 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.0427 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 1234000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0254 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 962700 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0198 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 650000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0134 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 600000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0123 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 564600 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0116 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 497000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0102 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 439600 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0090 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 400000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0082 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 340800 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0070 | |
| Number of shares held | CurrentQuarterInstant | 7759910 | |
| Shareholding ratio | CurrentQuarterInstant | 0.1600 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 6100 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 48487600 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 484876 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 10100 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 48503800 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 484876 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 6100 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 6100 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.000 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 6100 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 6100 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.000 | |
| Cash and deposits | Prior1YearInstant_NonConsolidatedMember | 1727270000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |